IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2934
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$21M
Eddie J. Sullivan
SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = SABS ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$SABS SAB Biotherapeutics, Inc. | 44 | 28 | 36 | 73 | 8.6x | 0.1x | 12.0% | 10.8% | - | - | - | -100.0% | 0.0% | 11.0x | $21M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
SAB Biotherapeutics, Inc. (SABS) receives a "Reduce" rating with a composite score of 44.2/100. It ranks #2934 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Eddie J. Sullivan
Chief Executive Officer
Labor Force
140
28
23
48
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for SABS
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for SABS.
View All RatingsHigh margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 28 | 6 | +22ALPHA |
| MOMENTUM | 73 | 75 | -2NEUTRAL |
| VALUATION | 36 | 15 | +21ALPHA |
| INVESTMENT | 23 | 6 | +17ALPHA |
| STABILITY | 48 | 31 | +17ALPHA |
| SHORT INT | 30 | 18 | +12ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 12.0% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth -100%, 5yr history
Interest coverage -292.9x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
SAB Biotherapeutics, Inc. receives a Reduce rating from our analysis, with a composite score of 44.2/100 and 2 out of 5 stars, ranking #2934 out of 7,333 stocks. SABS's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
SABS's quality score of 28/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 12.0% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 36/100, SABS appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 8.59x, an EV/EBITDA of 0.11x, a P/B ratio of 1.03x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
SAB Biotherapeutics, Inc.'s investment score of 23/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 5.9% and a return on assets of 10.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
SABS shows strong momentum characteristics with a score of 73/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at -100.0% year-over-year, while a beta of 0.96 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 48/100, SABS exhibits average financial resilience. Key stability metrics include a beta of 0.96 and a debt-to-equity ratio of 11.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
SAB Biotherapeutics, Inc.'s short interest score of 30/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 11.00x), micro-cap liquidity risk. At $21M (micro-cap), SABS carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
SAB Biotherapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2934 of 7,333 overall (60th percentile). Key comparisons include ROE of 12.0% exceeding the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SABS currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (23) would have the largest impact on the composite score.
EV/EBITDA 99% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 583% BELOW SECTOR MEDIAN
Debt/Equity 5400% ABOVE SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate SAB Biotherapeutics, Inc. (SABS) as a Reduce with a composite score of 44.2/100 at a current price of $3.73. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (73th percentile) and stability (48th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (23th percentile) and quality (28th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), Medium uncertainty, and Standard capital allocation.
Key items to watch: whether strong momentum is fundamentally supported by revenue trends. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
SAB Biotherapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 44.2/100 places it at rank #2934 in our full 7,333-stock universe. At $21M in market capitalization, SAB Biotherapeutics, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Despite positive momentum (73th percentile), revenue contraction of -100% creates a divergence between price action and fundamental trajectory. This divergence suggests either that the market is looking through near-term weakness or that technical factors are temporarily inflating the stock. Investors should assess whether the revenue decline reflects cyclical weakness or structural challenges.
Margin data is not available for SAB Biotherapeutics, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $3.73, SAB Biotherapeutics, Inc. is trading at a premium to fundamental value. Our value factor score of 36/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 8.6x (a 61% discount to the sector median of 22.3x), EV/EBITDA of 0.1x (discounted to peers), P/B of 1.0x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
A conservative balance sheet (11% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Positive momentum (73th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
Return on assets of 10.8% indicates efficient deployment of the full asset base, not just equity capital.
The Reduce rating (composite 44.2/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -100% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
We assign a Medium uncertainty rating to SAB Biotherapeutics, Inc.. The stock presents a balanced risk profile: weak quality scores (28th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: weak quality scores (28th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 48th percentile and quality factor at the 28th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (11% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate SAB Biotherapeutics, Inc.'s capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 12.0%, and the balance sheet is managed within acceptable parameters (D/E: 11%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; SAB Biotherapeutics, Inc. falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, SAB Biotherapeutics, Inc. receives a Reduce rating with a composite score of 44.2/100 (rank #2934 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), Medium uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 42/100.
Our analysis does not support a constructive view on SAB Biotherapeutics, Inc. at this time. The combination of limited competitive advantages, medium uncertainty, and standard capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign SAB Biotherapeutics, Inc. a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (9.1/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage -292.9x. These pillars form the core of SAB Biotherapeutics, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (1.4/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect SAB Biotherapeutics, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-100%) that pressure the earnings outlook. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 28th percentile.
Return metrics include ROE of 12.0% and ROA of 10.8%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of 12.0% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 11%, revenue growth of -100%. The sector median D/E is 0%, putting SAB Biotherapeutics, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (28th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081
SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a "Moderate Buy" consensus rating from six brokerage firms, with an average 12-month price target of $10.00. Institutional investors, including several hedge funds, have recently increased their holdings, now accounting for 7.82% of the stock. The clinical-stage biotech company, which develops polyclonal antibody therapeutics using its Tc Bovine® platform, is currently trading around $4 with a market cap of approximately $190 million and recently beat consensus EPS estimates.
UBS Group has upgraded SAB Biotherapeutics (NASDAQ:SABS) to a "Strong-Buy" rating, contributing to a consensus "Buy" rating among analysts with an average price target of $10.00. Despite opening down 2.8% at $3.86 with a market cap of $183.8M and negative earnings, the company beat its last quarterly EPS estimate. Several institutional investors have recently adjusted their holdings in SABS, with hedge funds and other institutional investors owning 7.82% of the company's stock.
Guggenheim has initiated coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and a $15.00 price target, suggesting a significant upside. The firm highlights SAB-142, a therapy for Stage 3 Type 1 Diabetes, as a key asset with potential for $2 billion in peak global sales. This comes amidst other positive developments for the company, including recent shareholder approvals and maintained Buy ratings from other analysts.
Chardan Capital has maintained its Buy recommendation for SAB Biotherapeutics (SABS) with an average one-year price target of $9.01/share, suggesting a 129.26% upside. The company is projected to see significant revenue growth and institutional ownership has increased, indicating a bullish outlook. Major institutional holders include Vivo Capital, Commodore Capital, and Ra Capital Management.
Chardan Capital has reiterated a "buy" rating for SAB Biotherapeutics (NASDAQ:SABS), setting a target price of $12.00, which suggests a potential upside of 203% from its previous close. Despite a consensus "Moderate Buy" rating from analysts with an average target of $9.33, the company recently exceeded quarterly EPS estimates, though analysts project a negative EPS for the current fiscal year. The stock opened at $3.96 with a market cap of approximately $188.5 million.